prikaz prve stranice dokumenta Prognostic implications of low transferrin saturation in patients with primary myelofibrosis
  Preuzmi
PDF 517.92 KB
Znanstveni rad - Izvorni znanstveni rad
Prognostic implications of low transferrin saturation in patients with primary myelofibrosis
Leukemia Research, 66 (2018); 89-95. https://doi.org/10.1016/j.leukres.2018.01.017
Lucijanić, Marko; Prka, Željko; Pejša, Vlatko; Štoos-Veić, Tajana; Lucijanić, Jelena; Kušec, Rajko

Citirajte ovaj rad

Lucijanić, M., Prka, Ž., Pejša, V., Štoos Veić, T., Lucijanić, J. i Kušec, R. (2018). Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. Leukemia Research, 66., 89-95. doi: 10.1016/j.leukres.2018.01.017

Lucijanić, Marko, et al. "Prognostic implications of low transferrin saturation in patients with primary myelofibrosis." Leukemia Research, vol. 66, 2018, str. 89-95. https://doi.org/10.1016/j.leukres.2018.01.017

Lucijanić, Marko, Željko Prka, Vlatko Pejša, Tajana Štoos Veić, Jelena Lucijanić i Rajko Kušec. "Prognostic implications of low transferrin saturation in patients with primary myelofibrosis." Leukemia Research 66 (2018): 89-95. https://doi.org/10.1016/j.leukres.2018.01.017

Lucijanić, M., et al. (2018) 'Prognostic implications of low transferrin saturation in patients with primary myelofibrosis', Leukemia Research, 66, str. 89-95. doi: 10.1016/j.leukres.2018.01.017

Lucijanić M, Prka Ž, Pejša V, Štoos Veić T, Lucijanić J, Kušec R. Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. Leukemia Research [Internet]. 03.2018. [pristupljeno 19.12.2024.];66:89-95. doi: 10.1016/j.leukres.2018.01.017

M. Lucijanić, Ž. Prka, V. Pejša, T. Štoos Veić, J. Lucijanić i R. Kušec, "Prognostic implications of low transferrin saturation in patients with primary myelofibrosis", Leukemia Research, vol. 66, str. 89-95, Ožujak 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:418058. [Citirano: 19.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:418058
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Prognostic implications of low transferrin saturation in patients with primary myelofibrosis
AutorMarko Lucijanić
AutorŽeljko Prka
AutorVlatko Pejša
AutorTajana Štoos-Veić
AutorJelena Lucijanić
AutorRajko Kušec
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
OBJECTIVES: Transferrin saturation (TSAT) 20% or less is considered to represent functional iron deficiency in the context of malignant disease, phenomenon mediated through inflammatory changes of iron homeostasis. We aimed to investigate clinical and prognostic significance of low TSAT in patients with primary (PMF) and secondary myelofibrosis (SMF), malignant diseases characterized by strong inflammatory milieu. ----- METHODS: We retrospectively analyzed 87 patients with myelofibrosis and compared TSAT with disease specific parameters. ----- RESULTS: One-third of patients had TSAT ≤20%. Lower TSAT was significantly associated with Janus-kinase-2 (JAK2) mutation (P = 0.007), transfusion independency (P = 0.003), higher platelets (P = 0.004), lower mean-corpuscular-volume (P < 0.001), lower ferritin (P < 0.001), higher absolute-neutrophil-count (P = 0.027), lower absolute-lymphocyte-count (P = 0.041) and lower albumin (P = 0.018). PMF patients presenting with low TSAT (≤20%) experienced significantly shorter overall-survival (OS) (HR = 2.43; P = 0.017), whereas TSAT did not affect OS of SMF patients (HR = 1.48; P = 0.623). Low TSAT remained significantly associated with inferior OS in PMF in a series of multivariate Cox regression models comparing its properties to anemia, transfusion dependency, ferritin and Dynamic-International-Prognostic-System (DIPSS). ----- CONCLUSIONS: Low TSAT has detrimental effect on survival of PMF patients. This effect is independent of anemia and of ferritin levels that seem to be better at representing iron overload in PMF patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaLeukemia Research
Brojčani podacivol. 66, str. 89-95
p-ISSN0145-2126
DOIhttps://doi.org/10.1016/j.leukres.2018.01.017
URN:NBNurn:nbn:hr:105:418058
Datum objave publikacije2018-03
URL dokumentahttps://doi.org/10.1016/j.leukres.2018.01.017
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:19:12